BioInvent International AB

BioInvent International AB

0.28
USD
-0.08
(-22.15%)
-0.74EPS
Mar 04Next Earn

Important Dates

Bioinvent International AB's next confirmed earnings release is scheduled for March 4, 2027.

Earnings Date3/4/2027

Share Statistics

As of September 30, 2026, Bioinvent International AB has 65.80M shares outstanding.

Shares Outstanding65.80M

Financial Position

As of September 30, 2026, Bioinvent International AB maintains a current ratio of 2.80, meaning it holds 2.8x the short-term assets needed to cover near-term liabilities.

Current Ratio2.80
Quick Ratio2.33
Debt / Equity9.62
Debt / EBITDA-0.04

Financial Efficiency

USD

These figures cover the twelve months ended September 30, 2026. The company generates approximately 36,680.77 in revenue per employee across its workforce of 109.00, a quick read on workforce productivity versus industry peers.

Revenue Per Employee36,680.77
Employee Count109.00

Taxes

USD

Over the twelve months ended September 30, 2026, Bioinvent International AB recorded 41,500.04 in income tax expense. The company reported a pretax loss of -48.64M and -48.68M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

Income Tax41,500.04

Stock Price Statistics

As of the close on November 9, 2026, Bioinvent International AB's stock has declined approximately 91.49% over the past 52 weeks.

52-Week Price Change-91.49%

Income Statement

USD

Over the twelve months ended September 30, 2026, Bioinvent International AB generated 4.00M in revenue and converted that into -48.68M in net income, yielding earnings per share of -0.74. EBITDA reached -47.85M, while operating income came in at -49.66M.

Revenue4.00M
Operating Income-49.66M
Pretax Income-48.64M
Net Income-48.68M
EBITDA-47.85M
EBIT-49.66M
Earnings Per Share (EPS)-0.74

Balance Sheet

USD

As of September 30, 2026, Bioinvent International AB holds 22.46M in cash and equivalents against 1.93M in total debt, resulting in a net debt position of -22.46M. Total book value stands at 20.09M, with working capital of 17.28M providing operational flexibility.

Cash & Cash Equivalents22.46M
Total Debt1.93M
Net Debt-22.46M
Equity (Book Value)20.09M
Book Value Per Share0.31
Working Capital17.28M

Cash Flow

USD

Bioinvent International AB produced -44.89M in operating cash flow over the twelve months ended September 30, 2026. After subtracting -271,300.27 in capital expenditures, free cash flow totaled -45.16M - equivalent to -0.69 per share.

Operating Cash Flow-44.89M
Capital Expenditures-271,300.27
Free Cash Flow-45.16M
FCF Per Share-0.69

Margins

These figures cover the twelve months ended September 30, 2026. The operating margin of -1,242.18 and net profit margin of -1,217.66 provide insight into operational efficiency.

Operating Margin-1,242.18
Pretax Margin-1,216.62
Profit Margin-1,217.66
EBITDA Margin-1,196.87

Stock Splits

Bioinvent International AB's most recent stock split took place on December 14, 2020 with a 25:1 split ratio.

Last Split Date12/14/2020
Split Ratio25:1